-
Economic Evaluation of Surfactant Therapy for Neonatal Respiratory Distress Syndrome: 5-Year Real-World Evidence on Poractant Alfa vs. Beractant From the IMSS Perspective in Mexico
Sep 9, 2025, 16:22 PM -
From GVD to HTA: Preparing for Success in the EU JCA Era With GenAI-Enhanced Efficiency
Sep 9, 2025, 16:22 PM -
Estimating the Eligible Population for Anti-Amyloid Therapy in Finland
Sep 9, 2025, 16:22 PM -
Quantifying the Fiscal Benefits of Obesity Prevalence Reduction in China: A Public Economic Perspective
Sep 9, 2025, 16:22 PM -
How Cost-Effectiveness and Budget Impact Drive Pricing and Reimbursement: Insights From an International Comparative Study
Sep 9, 2025, 16:22 PM -
Pegunigalsidase Alfa Elfabrio® as a Long-Term Enzyme Replacement Therapy in Adults With Fabry Disease: A Systematic Literature Review
Sep 9, 2025, 16:22 PM -
Organizational and Environmental Impact of Switching From Intravenous to Subcutaneous Immune Checkpoint Inhibitors (ICIs) in France: A Real-World Analysis Using PMSI Data
Sep 9, 2025, 16:22 PM -
A Collection Of Essays on Patient Centricity in Intervention Development
Sep 9, 2025, 16:22 PM -
What Is the Impact of Patient Voice on NICE Recommendations for Drugs Assessed in 2024?
Sep 9, 2025, 16:22 PM -
A Health Economic Evaluation of Daylight: A Digital Treatment for Anxiety in NHS South Yorkshire
Sep 9, 2025, 16:22 PM -
Real-World Analysis of Treatment Patterns and Disease Exacerbations Among Patients Initiating Therapy for Myasthenia Gravis
Sep 9, 2025, 16:22 PM -
Guideline-Driven Off-Label Oncology Use: The Role of Clinical Evidence and Reimbursement Dynamics in the EU4+UK, Switzerland, and Canada
Sep 9, 2025, 16:22 PM -
Patients’ Advocacy Groups in Italy: An Updated Perspective on Activities and Future Directions
Sep 9, 2025, 16:22 PM -
Use of Data From Phase 3 RCTs in Earlier Lines of Therapy in Support of Noncomparative Evidence From Pivotal Phase 2 Studies
Sep 9, 2025, 16:22 PM -
Developing Best Practice for Generative AI in Health Economic Evaluation: Evidence From a Systematic Review and Stakeholder Engagement
Sep 9, 2025, 16:22 PM -
Evolving Trends in Patient Demographics and Diagnosis in Gastric Cancer: A Real-World Analysis From US Community Oncology Practices From 2014 to 2024
Sep 9, 2025, 16:22 PM -
Understanding Trends and Opinions on More Environmentally Friendly Healthcare: A Clinician Survey
Sep 9, 2025, 16:22 PM -
Comparing the Time to Reimbursement of the Orphan Drug Evrysdi in Turkiye vs. Euro-5 Markets
Sep 9, 2025, 16:22 PM -
Incidence of Adverse Events and Costs Among Patients Initiating Treatment for Myasthenia Gravis: A Real-World Analysis
Sep 9, 2025, 16:22 PM -
Use of RWE in HTA Submissions: A Systematic Review of Case Studies Across Three HTA Agencies Reveals Continued Concerns Around Internal Validity and Unmeasured Confounding
Sep 9, 2025, 16:22 PM
